This approach enables an ongoing dialogue between the regulatory body and drug developers. Expediting the review process ...

However, the biotech and pharmaceutical companies that develop these therapies do so at great expense. High drug development ...

The research also highlights potential avenues for repurposing existing drugs. Researchers found that trimethoprim and ...

FRANKFURT, Nov 14 (Reuters) - Merck KGaA (MRCG.DE), opens new tab on Thursday reported a gain of 11.9% in adjusted quarterly ...

Following strong treatment response data for Adaptimmune’s lete-cel, the biotech is planning to initiate a rolling BLA ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

Anish Suri, Ph.D., president & chief scientific officer (CSO) of Cue Biopharma, to transition to principal research and immunology advisor BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.

BioNTech said the deal will support its push into the development of cancer drugs using its proven mRNA technology, in addition to other methods including cell and protein-based therapeutics. In ...

including pharmaceutical development, genetic engineering, models for regulatory reform, precision medicine, and the ...

Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...

Arcturus Therapeutics (ARCT) is continuing to evaluate the use of LUNAR-CF [ARCT-032] for the treatment of patients with Cystic Fibrosis [CF]. Read our latest report on the stock here.